Advancing Cancer Care for Dogs
Transforming canine cancer treatment through personalized medicine.
FidoCure® Precision Medicine for Canine Cancer
There’s no “one-size-fits-all” treatment for cancer. That’s why FidoCure® uses genomic testing to determine the best course of action for your dog’s cancer therapy – beyond standard chemo and radiation.
FidoCure® Approach: Genetic testing reveals which targeted therapies may work best for your dog
Precision medicine can offer a hopeful prognosis. FidoCure® was created by dog lovers and scientists on a mission to make effective canine cancer treatment accessible. Our process uses genomic testing in conjunction with tumor type to identify possible cancer-causing mutations. From there, we suggest targeted therapy to precisely attack the cancer cells.
Forrest was diagnosed with splenic cancer and given one month to live.
Through the targeted therapy suggested by FidoCure®, he lived happily for nearly 4 years past his diagnosis.
Forrest, Golden Retriever
Hemophagocytic Histiocytic Sarcoma
Trusted by the Leading Veterinary Oncologists
Thousands of dogs have benefitted from FidoCure® when other options were limited.
“Since starting treatment, Toulouse’s tumors have regressed. FidoCure® brought us hope for Toulouse when we thought we didn’t have any options left.” — Daniel, FL
“Thanks to FidoCure®, Lizzie is 100% active again, eating well, and in remission for 5 months.” — Kimberley and Francois, CT
“[Our vet] told us about the One Health Company’s precision medicine solution, FidoCure®… Now, exactly two months later, Gracie’s cancer is in remission.” — The Gonzalez Family, FL
Resources & Education
- Hemangiosarcoma: Advancing canine cancer treatment with targeted therapiesby FidoCure
Canine cancer diagnoses can be devastating and demoralizing. While research and studies for human cancer have brought us a long way when it […]
- Splenic Hemangiosarcoma Case Study: Pitaby Dr. Dorothy Jackson Girimonte in Case Studies
With a combination approach that included FidoCure® therapy, Pita lived for a year following a hemoabdomen and diagnosis of splenic […]
- Research featured in The Cancer Letterby Christina K. Lopes
We were thrilled to see our recent Nature paper featured in last week's issue of The Cancer Letter! Our multi-year study has compared […]
- TCC Case Study: Sir Oliverby Dr. Gerry Post in Case Studies
Sir Oliver, an 8 year old French Bulldog with TCC, is surviving and thriving thanks to his targeted therapeutic treatment4.5 months from […]
- Mammary Carcinoma Case Study: Missyby Dr. Gerry Post in Case Studies
After one year of FidoCure®targeted therapy, Missy showed no evidence of pulmonary metastatic disease.
- Squamous Cell Carcinoma Case Study: Duchessby Dr. Gerry Post in Case Studies
It is clear that the utilization of targeted therapy has proven beneficial in improving patient quality of life, extending survival time […]